Boxer Capital, LLC - Aug 23, 2023 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role
Other*
Signature
/s/ Aaron I. Davis, Chief Executive Officer, Boxer Capital, LLC
Stock symbol
ITOS
Transactions as of
Aug 23, 2023
Transactions value $
-$5,692,673
Form type
4
Date filed
8/25/2023, 09:28 PM
Previous filing
Aug 15, 2023
Next filing
Oct 11, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITOS Common Stock Sale -$494K -34.8K -1.62% $14.19 2.12M Aug 23, 2023 Direct F1, F2
transaction ITOS Common Stock Sale -$1.49M -95.5K -4.51% $15.63 2.02M Aug 23, 2023 Direct F2, F3
transaction ITOS Common Stock Sale -$3.71M -220K -10.85% $16.87 1.8M Aug 23, 2023 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.80 to $14.59, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Asset Management Inc. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.05 to $15.85, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.50 to $17.04, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Remarks:

Aaron Davis, the CEO of Boxer Capital, LLC, is a director of iTeos Therapeutics, Inc. (the "Issuer"). The reporting persons other than Mr. Davis previously reported ceasing to be subject to Section 16 of the Exchange Act with respect to the Issuer. This filing is being made by those other reporting persons without conceding that they are subject to Section 16 of the Exchange Act with respect to the Issuer.